Skip Navigation Links

Bookmark and Share
Daiichi Sankyo Initiates Phase 1 Trial with Immuno-Oncology Therapy DS-1055 Targeting GARP on Activated Regulatory T Cells
First-in-human phase 1 study to evaluate DS-1055 as a new type of immune intervention for patients with relapsed/refractory advanced or metastatic solid tumors Daiichi Sankyo combines novel technologies with expertise in antibody biology to create ...

Full "IntellAsia: Resources" article

Disclaimer | Terms Of Use And Privacy Statement

© Metals News. All rights reserved.